Cannabinoids Show Anticancer Properties in Lab and Animal Studies, But Clinical Evidence Is Limited

Preclinical studies show cannabinoids can inhibit cancer cell proliferation, stimulate cell death, and potentially block tumor blood supply and metastasis, but human clinical trial data remains sparse.

Śledziński, Paweł et al.·Cancer medicine·2018·Moderate EvidenceReview
RTHC-01839ReviewModerate Evidence2018RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Cannabinoids exhibit anticancer properties through multiple mechanisms: inhibiting cell proliferation, stimulating autophagy and apoptosis, and potentially inhibiting angiogenesis and metastasis. However, the review also discusses cases where cannabinoids stimulated cancer cell proliferation, and notes the complex role of the endocannabinoid system in cancer development.

Key Numbers

Multiple signaling pathways identified, including those controlling cell proliferation and survival. Both in vitro and in vivo evidence reviewed across multiple cancer types.

How They Did This

Review of in vitro and in vivo preclinical evidence for cannabinoid anticancer activity, molecular mechanisms, and currently ongoing clinical trials.

Why This Research Matters

While cannabinoids are currently approved only for palliative cancer care (pain and nausea), growing preclinical evidence suggests they may have direct anticancer properties. Understanding both the promise and complexity is essential for responsible research translation.

The Bigger Picture

The review highlights that cannabinoid-cancer interactions are not uniformly anti-tumor. Some evidence suggests cannabinoids can stimulate cancer cell proliferation under certain conditions, and the endocannabinoid system's role in carcinogenesis itself is not fully understood.

What This Study Doesn't Tell Us

Most evidence is preclinical. In vitro conditions differ significantly from human tumors. Dosing in animal studies may not translate to humans. Limited clinical trial data available at time of review.

Questions This Raises

  • ?Under what conditions might cannabinoids promote rather than inhibit cancer growth?
  • ?Which cancer types are most responsive to cannabinoid treatment?
  • ?Could cannabinoids enhance the effectiveness of conventional chemotherapy?

Trust & Context

Key Stat:
Cannabinoids showed anticancer effects through proliferation inhibition, autophagy and apoptosis stimulation, and anti-angiogenesis, but some studies found cancer cell stimulation.
Evidence Grade:
Moderate - comprehensive review of substantial preclinical evidence, but clinical trial data was sparse at time of publication.
Study Age:
Published in 2018. Several clinical trials evaluating cannabinoids as anticancer agents have since progressed.
Original Title:
The current state and future perspectives of cannabinoids in cancer biology.
Published In:
Cancer medicine, 7(3), 765-775 (2018)
Database ID:
RTHC-01839

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

Can cannabis cure cancer?

Preclinical studies (lab and animal) show cannabinoids can kill cancer cells and inhibit tumor growth through multiple mechanisms. However, human clinical trial evidence is still limited, and some studies have found cannabinoids can stimulate cancer cell growth under certain conditions.

How might cannabinoids fight cancer?

Lab studies show cannabinoids can inhibit cancer cell proliferation, trigger programmed cell death (apoptosis and autophagy), and potentially block the formation of blood vessels that feed tumors (angiogenesis) and cancer spread (metastasis).

Read More on RethinkTHC

Cite This Study

RTHC-01839·https://rethinkthc.com/research/RTHC-01839

APA

Śledziński, Paweł; Zeyland, Joanna; Słomski, Ryszard; Nowak, Agnieszka. (2018). The current state and future perspectives of cannabinoids in cancer biology.. Cancer medicine, 7(3), 765-775. https://doi.org/10.1002/cam4.1312

MLA

Śledziński, Paweł, et al. "The current state and future perspectives of cannabinoids in cancer biology.." Cancer medicine, 2018. https://doi.org/10.1002/cam4.1312

RethinkTHC

RethinkTHC Research Database. "The current state and future perspectives of cannabinoids in..." RTHC-01839. Retrieved from https://rethinkthc.com/research/sledzinski-2018-the-current-state-and

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.